Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative antiviral therapy in hepatitis B-related hepatocellular carcinoma
ChiCTR1900024098Phase 4Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Jul 2019
- Modality
- Small Molecules, Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of entecavir, tenofovir, thymopentin and thymosin alpha 1 in hepatocellular carcinoma (HCC) and hepatitis B (HBV) (6 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Biochemical response and Virological response. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
entecavirtenofovirthymopentinthymosin alpha 1
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR1900024098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024098.